特发性间质性肺炎伴血小板减少抗感染治疗1例

摘要
图/表
参考文献
相关文章 (8)

[1]	徐作军.回顾与展望:特发性间质性肺炎的临床研究[J].协和医学杂志,2018,9(3):202-206.
[2]	武晓辉.浅析特发性间质性肺炎的诊断和治疗措施[J].世界最新医学信息文摘,2019,19(23):91-92.
[3]	Youhei T, Atsushi S, Hirofumi C, et al. Impaired diversity of the lung microbiome predicts progression of idiopathic pulmonary fibrosis[J]. Respir Res, 2018,19(1):34.
[4]	Motoyasu K, Tomoko Y, Shunichi K, et al. Prognostic differences among patients with idiopathic interstitial pneumonias with acute exacerbation of varying pathogenesis: a retrospective study[J]. Respir Res,2019,20(1):287.
[5]	贾建军,刘瑞娟,王留新,等.高分辨CT及经支气管镜肺活检、C反应蛋白在弥漫性间质性肺病的临床病理研究[J].中国内镜杂志,2015,21(6):631-635.
[6]	Braedon M, Mary D. Platelets and intravascular immunity: guardians of the vascular space during bloodstream infections and sepsis [J]. Front Immunol,2019,10:2400.
[7]	苏天皎,赵久法.感染性疾病伴血小板减少症的临床分析[J].血栓与止血学,2019,25(2):185-189.
[8]	Lu H W, Ji X B, Liang S, et al. Pathogen characteristics reveal novel antibacterial approaches for interstitial lung disease [J].Pulm Pharmacol Ther,2014,29(2):250-254.
[9]	李蓓,骆文玲,解晓悦,等.2012-2016年本医院内获得性肺炎病原菌分布及革兰阴性杆菌耐药性分析[J].武警医学,2017,28(11):1151-1154.
[10]	毛娇娇,潘杰.质子泵抑制药致血液系统不良反应的特点及机制分析[J].中国药物警戒,2019,16(2):119-122.
[11]	罗兴献,刘一,薛学财,等.55例喹诺酮类药物致血小板减少症文献分析[J].中国临床药学杂志,2018,27(3):188-191.
[12]	Tuccori M, Benedetta G, Giovanni C, et al.Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome [J].Platelets,2008,19( 5):384-387.
[13]	李耘,吕媛,郑波,等.中国细菌耐药监测研究2017-2018革兰氏阴性菌监测报告[J].中国临床药理学杂志,2019,35(19):2508-2528.
[14]	Caroline B, Lisa K, Vishal Y.Cefepime challenge after piperacillin/tazobactam-induced thrombocytopenia[J].J Thromb Thrombolysis, 2019,48(1):167-170.